MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Plerixafor

CAS No. : 110078-46-1

MCE 站：Plerixafor

产品活性：Plerixafor (AMD 3100) 是选择性的 CXCR4 拮抗剂，IC₅₀ 为 44 nM。Plerixafor 是一种免疫刺激剂和造血干细胞动员剂，也是 CXCR7 的变构激动剂。Plerixafor 抑制 HIV-1 和 HIV-2 的复制，EC₅₀ 为 1-10 nM。

研究领域：GPCR/G Protein  |  Immunology/Inflammation  |  Anti-infection

作用靶点：CXCR  |  HIV  |  Virus Protease

In Vitro: The CXCR4 inhibitor Plerixafor (AMD3100) is a potent inhibitor of CXCL12-mediated chemotaxis (IC₅₀, 5.7 nM) with a potency slightly better than its affinity for CXCR4. Plerixafor interferes with the interaction of CXCR4 with its natural ligand, SDF-1 (CXCL12). Treating the cells with CCX771 or CXCL11 has no effect on CXCL12-mediated MOLT-4 or U937 TEM. In contrast, 10 μM Plerixafor inhibits CXCL12-mediated TEM in both cells lines
. Plerixafor prevents the infiltration of tumor-associated macrophages (TAMs) into the tumor tissues.

In Vivo: Plerixafor (2 mg/kg) administration to UUO mice exacerbates renal interstitial T cell infiltration, resulting in increased production of the pro-inflammatory cytokines IL-6 and IFN-γ and decreased expression of the anti-inflammatory cytokine IL-10.
Both perivascular and interstitial fibrosis are significantly reduced by the CXCR4 antagonist, Plerixafor (AMD3100) at 8 weeks. LD50, mouse, SC: 16.3 mg/kg; LD50, rat, SC: >50 mg/kg; LD50, mouse and rat, IV injection: 5.2 mg/kg.

相关产品：Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  Anti-Infection Compound Library  |  GPCR/G Protein Compound Library  |  Immunology/Inflammation Compound Library  |  FDA-Approved Drug Library  |  Anti-Cancer Compound Library  |  Antiviral Compound Library  |  Small Molecule Immuno-Oncology Compound Library  |  Peptidomimetic Library  |  Drug Repurposing Compound Library  |  Diabetes Related Compound Library  |  Endocrinology Compound Library  |  Anti-COVID-19 Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Drug-Induced Liver Injury (DILI) Compound Library  |  Doxorubicin hydrochloride  |  Chloroquine  |  5-Fluorouracil  |  4-Phenylbutyric acid  |  Valproic acid  |  (-)-Epigallocatechin Gallate  |  Shikonin  |  Glycyrrhizic acid  |  Ivermectin  |  Aspirin  |  Ebselen  |  Dynasore  |  Kaempferol  |  Flavopiridol  |  Maraviroc  |  Hydroxyurea  |  Dimethyl fumarate  |  SB225002  |  Artesunate  |  Baicalin  |  Probenecid  |  Ritonavir  |  Fasudil Hydrochloride  |  Lopinavir  |  Betulinic acid  |  Lamivudine  |  Reparixin  |  Rolipram

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。